Olema Pharmaceuticals (OLMA) Receivables - Other (2021 - 2026)

Olema Pharmaceuticals (OLMA) has reported Receivables - Other for 6 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other rose 72.97% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 72.97% YoY), while the FY2025 annual figure was $3.1 million, up 47.97% from the prior year.
• Receivables - Other climbed to $3.3 million in Q1 2026 per OLMA's latest filing, from $3.1 million in the prior quarter.
• Across five years, Receivables - Other topped out at $3.3 million in Q1 2026 and bottomed at $221000.0 in Q2 2023.
• Historically, Receivables - Other has averaged $1.3 million across 5 years, with a median of $687000.0 in 2024.
• Annual changes were most pronounced in 2023 — Receivables - Other dropped 8.32% — and 2024, when it soared 271.49%.
• Olema Pharmaceuticals' Receivables - Other stood at $319000.0 in 2022, then surged by 110.97% to $673000.0 in 2023, then jumped by 215.01% to $2.1 million in 2024, then surged by 47.97% to $3.1 million in 2025, then increased by 5.87% to $3.3 million in 2026.
• Business Quant data shows OLMA's Receivables - Other at $3.3 million in Q1 2026, $3.1 million in Q4 2025, and $2.1 million in Q3 2025.